Track Protalix BioTherapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Protalix BioTherapeutics, Inc. PLX · Stock Open Protalix BioTherapeutics, Inc. in new tab

3.05 USD
P/E
12.35
EPS
0.24
P/B
3.04
ROE
30.80
Beta
-0.02
Target Price
11.00 USD
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc.

🧾 Earnings Recap – Q3 2025

Protalix BioTherapeutics reported strong year-to-date revenue growth of 24%, though third-quarter revenues showed a slight decline of 1% compared to the previous year, reflecting ongoing inventory management by key partners.

  • Total revenues for the first nine months of 2025 reached $46.4 million, marking a 24% year-over-year increase.
  • Third-quarter revenue was $17.9 million, down 1% year-over-year due to variable inventory control by partners.
  • The company is advancing its PRX-115 candidate for the treatment of uncontrolled gout, having filed for a Phase 2 clinical trial.
  • Research and development expenses surged by 58% for the first nine months, emphasizing continued investment in pipeline projects.
  • Protalix maintains a strong cash position and positive net income, supporting its strategic focus on commercial success and innovation.
📅
Loading chart...
Key Metrics
Earnings dateMarch 17, 2027
P/E12.35
EPS0.24
Book Value0.98
Price to Book3.04
Debt/Equity11.35
% Insiders3.705%
Growth
Revenue Growth0.23%
Earnings Growth0.66%
Estimates
Forward P/E4.78
Forward EPS0.62
Target Mean Price11.00

DCF valuation

Model fair value for Protalix BioTherapeutics, Inc. (PLX)
Result
Sign in to run the valuation for PLX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus Strong buy · mean target 11.00 USD (low 10.00, high 12.00) · as of 12 Nov 2026
Low 10.00
Mean 11.00
High 12.00
Price 3.05
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Protalix BioTherapeutics, Inc. Logo Protalix BioTherapeutics, Inc. Analysis (PLX)

Israel Health Care Official Website Stock

Is Protalix BioTherapeutics, Inc. a good investment? Protalix BioTherapeutics, Inc. (PLX) is currently trading at 3.05 USD. Market analysts have a consensus price target of 11.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 12.35. This relatively low multiple may signal that Protalix BioTherapeutics, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Protalix BioTherapeutics, Inc. is expected to release its next earnings report on March 17, 2027. The market consensus estimate for Forward EPS is 0.62.

Investor FAQ

Does Protalix BioTherapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Protalix BioTherapeutics, Inc.?

Protalix BioTherapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 17, 2027. The company currently has a trailing EPS of 0.24.

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

Exchange Ticker
FRA (Germany) PBDA.F
ASE (United States) PLX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 3, 2007 1:10
Dec. 20, 2019 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion